Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians...
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
February 28, 2023 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces CEO Transition and Business Update
January 31, 2023 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Paul Spence as Chief Commercial Officer
December 15, 2022 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Departure of Acting Chief Financial Officer
December 09, 2022 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
November 30, 2022 07:00 ET
|
Optinose, Inc.
$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis Revised Note Purchase Agreement Extends Start of...
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
November 21, 2022 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 21, 2022 06:12 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
November 10, 2022 07:00 ET
|
Optinose, Inc.
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps...